Nanocarriers for Targeted Drug Delivery in the Vascular System: Focus on Endothelium

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Oct 12

PMID 39396002

Authors

Xiuxiu Cong

Zebin Zhang

He Li

Yong-Guang Yang

YuNing Zhang

Tianmeng Sun

Affiliations

Soon will be listed here.

Abstract

Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics, and modulating inflammatory responses. Nanocarriers hold transformative potential for precise drug delivery within the vascular system, particularly targeting ECs for therapeutic purposes. However, the complex interactions between vascular ECs and nanocarriers present significant challenges for the development and clinical translation of nanotherapeutics. This review assesses recent advancements and key strategies in employing nanocarriers for drug delivery to vascular ECs. It suggested that through precise physicochemical design and surface modifications, nanocarriers can enhance targeting specificity and improve drug internalization efficiency in ECs. Additionally, we elaborated on the applications of nanocarriers specifically designed for targeting ECs in the treatment of cardiovascular diseases, cancer metastasis, and inflammatory disorders. Despite these advancements, safety concerns, the complexity of in vivo processes, and the challenge of achieving subcellular drug delivery remain significant obstacles to the effective targeting of ECs with nanocarriers. A comprehensive understanding of endothelial cell biology and its interaction with nanocarriers is crucial for realizing the full potential of targeted drug delivery systems.

Citing Articles

Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy.

Chen Q, Yu T, Gong J, Shan H Molecules. 2025; 30(4).

PMID: 40005272 PMC: 11858567. DOI: 10.3390/molecules30040962.

Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.

Toader C, Radoi M, Covlea C, Covache-Busuioc R, Ilie M, Glavan L Int J Mol Sci. 2024; 25(22).

PMID: 39595942 PMC: 11593836. DOI: 10.3390/ijms252211874.

Nanoparticle-Mediated Delivery of Deferasirox: A Promising Strategy Against Invasive Aspergillosis.

Peppe S, Farrokhi M, Waite E, Muhi M, Matthaiou E Bioengineering (Basel). 2024; 11(11).

PMID: 39593775 PMC: 11591955. DOI: 10.3390/bioengineering11111115.

References

Zhan Y, Dai Y, Ding Z, Lu M, He Z, Chen Z . Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke. Front Bioeng Biotechnol. 2024; 11:1329959. PMC: 10869484. DOI: 10.3389/fbioe.2023.1329959. View

Tang Y, Yu Z, Lu X, Fan Q, Huang W . Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines. Adv Sci (Weinh). 2022; 9(13):e2103148. PMC: 9069202. DOI: 10.1002/advs.202103148. View

Chehelgerdi M, Chehelgerdi M, Allela O, Pecho R, Jayasankar N, Rao D . Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023; 22(1):169. PMC: 10561438. DOI: 10.1186/s12943-023-01865-0. View

Wang X, Liang Q, Mao Y, Zhang R, Deng Q, Chen Y . Bioreducible, branched poly(β-amino ester)s mediate anti-inflammatory ICAM-1 siRNA delivery against myocardial ischemia reperfusion (IR) injury. Biomater Sci. 2020; 8(14):3856-3870. DOI: 10.1039/d0bm00631a. View

Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kroller-Schon S . New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. Int J Mol Sci. 2019; 20(1). PMC: 6337296. DOI: 10.3390/ijms20010187. View

Marcos-Contreras O, Greineder C, Kiseleva R, Parhiz H, Walsh L, Zuluaga-Ramirez V . Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc Natl Acad Sci U S A. 2020; 117(7):3405-3414. PMC: 7035611. DOI: 10.1073/pnas.1912012117. View

Oladipo A, Lebelo S, Msagati T . Nanocarrier design-function relationship: The prodigious role of properties in regulating biocompatibility for drug delivery applications. Chem Biol Interact. 2023; 377:110466. DOI: 10.1016/j.cbi.2023.110466. View

Yan J, Wang Y, Zhang J, Liu X, Yu L, He Z . Rapidly Blocking the Calcium Overload/ROS Production Feedback Loop to Alleviate Acute Kidney Injury via Microenvironment-Responsive BAPTA-AM/BAC Co-Delivery Nanosystem. Small. 2023; 19(17):e2206936. DOI: 10.1002/smll.202206936. View

Simion V, Constantinescu C, Stan D, Deleanu M, Tucureanu M, Butoi E . P-Selectin Targeted Dexamethasone-Loaded Lipid Nanoemulsions: A Novel Therapy to Reduce Vascular Inflammation. Mediators Inflamm. 2016; 2016:1625149. PMC: 5039295. DOI: 10.1155/2016/1625149. View

10.

Howard M, Greineder C, Hood E, Muzykantov V . Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release. 2014; 177:34-41. PMC: 4593476. DOI: 10.1016/j.jconrel.2013.12.035. View

11.

Yang H, Liu T, Xu Y, Su G, Liu T, Yu Y . Protein corona precoating on redox-responsive chitosan-based nano-carriers for improving the therapeutic effect of nucleic acid drugs. Carbohydr Polym. 2021; 265:118071. DOI: 10.1016/j.carbpol.2021.118071. View

12.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

13.

Tee J, Yip L, Tan E, Santitewagun S, Prasath A, Ke P . Nanoparticles' interactions with vasculature in diseases. Chem Soc Rev. 2019; 48(21):5381-5407. DOI: 10.1039/c9cs00309f. View

14.

Han J, Zern B, Shuvaev V, Davies P, Muro S, Muzykantov V . Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano. 2012; 6(10):8824-36. PMC: 3874124. DOI: 10.1021/nn302687n. View

15.

Howard M, Zern B, Anselmo A, Shuvaev V, Mitragotri S, Muzykantov V . Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano. 2014; 8(5):4100-32. PMC: 4046791. DOI: 10.1021/nn500136z. View

16.

Homem de Bittencourt Jr P, Lagranha D, Maslinkiewicz A, Senna S, Tavares A, Baldissera L . LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis. 2006; 193(2):245-58. DOI: 10.1016/j.atherosclerosis.2006.08.049. View

17.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

18.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

19.

Cong V, Houng J, Kavallaris M, Chen X, Tilley R, Gooding J . How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?. Chem Soc Rev. 2022; 51(17):7531-7559. DOI: 10.1039/d1cs00707f. View

20.

Voigt J, Christensen J, Shastri V . Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae. Proc Natl Acad Sci U S A. 2014; 111(8):2942-7. PMC: 3939899. DOI: 10.1073/pnas.1322356111. View